ATE334986T1 - Triptpolidanaloge zur verendung in der behandlung von autoimmunbedingten und entzündlichen erkrankungen - Google Patents

Triptpolidanaloge zur verendung in der behandlung von autoimmunbedingten und entzündlichen erkrankungen

Info

Publication number
ATE334986T1
ATE334986T1 AT01977423T AT01977423T ATE334986T1 AT E334986 T1 ATE334986 T1 AT E334986T1 AT 01977423 T AT01977423 T AT 01977423T AT 01977423 T AT01977423 T AT 01977423T AT E334986 T1 ATE334986 T1 AT E334986T1
Authority
AT
Austria
Prior art keywords
autoimmune
treatment
triptpolide
analogues
inflammatory diseases
Prior art date
Application number
AT01977423T
Other languages
English (en)
Inventor
Hariharan Venkatesan
James P Snyder
Dennis C Liotta
Susheng Wang
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Application granted granted Critical
Publication of ATE334986T1 publication Critical patent/ATE334986T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/04—Compounds containing oxirane rings containing only hydrogen and carbon atoms in addition to the ring oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/001—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by modification in a side chain
    • C07C37/002—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by modification in a side chain by transformation of a functional group, e.g. oxo, carboxyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46—Friedel-Crafts reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/14—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by free hydroxyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/32—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by aldehydo- or ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Epoxy Compounds (AREA)
AT01977423T 2000-10-02 2001-10-02 Triptpolidanaloge zur verendung in der behandlung von autoimmunbedingten und entzündlichen erkrankungen ATE334986T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23755700P 2000-10-02 2000-10-02

Publications (1)

Publication Number Publication Date
ATE334986T1 true ATE334986T1 (de) 2006-08-15

Family

ID=22894243

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05077239T ATE469907T1 (de) 2000-10-02 2001-10-02 Triptolid-analoga zur behandlung von autoimmunkranheiten und entzündungen
AT01977423T ATE334986T1 (de) 2000-10-02 2001-10-02 Triptpolidanaloge zur verendung in der behandlung von autoimmunbedingten und entzündlichen erkrankungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT05077239T ATE469907T1 (de) 2000-10-02 2001-10-02 Triptolid-analoga zur behandlung von autoimmunkranheiten und entzündungen

Country Status (8)

Country Link
US (3) US6777441B2 (de)
EP (2) EP1659125B1 (de)
JP (2) JP4269144B2 (de)
AT (2) ATE469907T1 (de)
AU (2) AU2001296542B2 (de)
CA (1) CA2424555A1 (de)
DE (2) DE60121986T2 (de)
WO (1) WO2002028862A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001296542B2 (en) 2000-10-02 2007-10-25 Emory University Triptolide analogs for the treatment of autoimmune and inflammatory disorders
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
JP4680589B2 (ja) * 2002-05-31 2011-05-11 ファーマジェネシス， インコーポレイテッド アポトーシスおよび免疫抑制の調節のためのトリプトリド誘導体
US20040053902A1 (en) * 2002-09-13 2004-03-18 Smith C. Steven Novel composition and method for treatment of upper respiratory conditions
JP2006517969A (ja) * 2003-02-14 2006-08-03 コンビナトアールエックス インコーポレーティッド 免疫炎症性障害の治療のための組み合わせ療法
JP4886511B2 (ja) * 2003-07-30 2012-02-29 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法
US20050192261A1 (en) * 2003-09-15 2005-09-01 Jost-Price Edward R. Methods and reagents for the treatment of immunoinflammatory disorders
US7820834B2 (en) * 2003-12-24 2010-10-26 Pharmagenesis, Inc. Triptolide 5,6-derivatives as immunomodulators and anticancer agents
EP1722806A4 (de) * 2004-02-09 2009-09-16 Pharmagenesis Inc Verfahren zur isolierung von triptolid-verbindungen aus tripterygium wilfordii
ES2385716T3 (es) * 2004-03-02 2012-07-30 Pharmagenesis, Inc. Derivados en el anillo de lactona de triptolida como inmunomoduladores y agentes anticáncer
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
WO2006012204A2 (en) * 2004-06-25 2006-02-02 Pharmagenesis, Inc. Method for treatment of inflammatory disorders using triptolide compounds
US8617906B2 (en) * 2004-10-13 2013-12-31 Pharmagenesis, Inc. Identification and screening of triptolide target molecules
CA2627242A1 (en) * 2005-10-31 2007-05-10 Rigel Pharmaceuticals, Inc. Compositions and methods for treating inflammatory disorders
WO2009089285A2 (en) * 2008-01-07 2009-07-16 Emory University Branched diepoxide compounds for the treatment of inflammatory disorders
WO2011041542A2 (en) 2009-09-30 2011-04-07 Ultimaxx, Inc. Herbal pain killer compositions
CN104478832B (zh) * 2015-01-05 2016-04-20 项敬来 二萜化合物，含其的药物组合物及其制备方法和应用
EP3344642A1 (de) * 2015-09-02 2018-07-11 AbbVie Inc. Antivirale tetrahydrofuranderivate

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1179866A (en) 1967-09-08 1970-02-04 Agfa Gevaert Nv Photopolymerisation of Ethylenically Unsaturated Organic Compounds
US3917652A (en) 1968-04-29 1975-11-04 Hoffmann La Roche Juvabione and derivatives thereof
BE789948A (fr) 1971-10-13 1973-04-11 Sandoz Sa Nouveaux derives du pyrazole, leur preparation et leur application comme medicaments
US3816437A (en) 1972-12-22 1974-06-11 Sandoz Ag Thieno(2,3-g)indazoles
US3957816A (en) 1973-01-31 1976-05-18 Sandoz, Inc. Substituted naphtho pyrazoles
JPS5473766A (en) 1977-11-21 1979-06-13 Nippon Terpen Kagaku Kk Manufacture of menthofuran
GB2104516B (en) * 1981-07-13 1985-12-04 Univ Brunel M-alkylphenol derivatives and their use in copper extraction
DE3219048A1 (de) 1982-05-21 1983-11-24 Basf Ag, 6700 Ludwigshafen Thermoplastische formmassen
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE3440826A1 (de) 1983-11-10 1985-05-23 Basf Ag, 6700 Ludwigshafen 1,1-ethanoretinsaeuren und ihre c(pfeil abwaerts)1(pfeil abwaerts)-c(pfeil abwaerts)4(pfeil abwaerts)-alkylester
JPS61197573A (ja) 1985-02-26 1986-09-01 Chugai Pharmaceut Co Ltd ５，６−エポキシ化トランスビタミンｄ３
WO1990002744A1 (en) 1988-09-15 1990-03-22 The Upjohn Company In position 3 substituted-5-beta-amidomethyl-oxazolidin-2-ones
DE3913310A1 (de) 1989-04-20 1990-10-25 Schering Ag Spirocyclopropane in der vitamin d-reihe
JPH03197464A (ja) 1989-12-16 1991-08-28 Basf Ag 置換アゾリルメチルシクロアルカノール及びこれを含有する殺菌剤
US5430054A (en) * 1989-12-22 1995-07-04 Jiangsu Family Planning Institute Preparation methods of diterpene lactone compounds and application of the same to antifertility
AU7570191A (en) * 1990-03-14 1991-10-10 Board Of Regents, The University Of Texas System Tripterygium wilfordii hook f extracts and components thereof for immunosuppression
US5216175A (en) 1990-03-23 1993-06-01 Sri International Antimalarial analogs of artemisinin
US5581004A (en) 1991-09-23 1996-12-03 Board Of Regents Of The University Of Nebraska Preparation and use of (2-butene-1,4-diyl) magnesium complexes in organic synthesis
WO1994002540A1 (en) 1992-07-22 1994-02-03 Lucey Michael F Highly filled polymeric compositions
AU6826194A (en) * 1993-05-06 1994-12-12 Pharmagenesis, Inc. 16-hydroxytriptolide composition and method for immunotherapy
FR2707992B1 (fr) 1993-07-21 1995-10-13 Flamel Tech Sa Nouveaux produits organiques contenant des fonctions thiols réactives, l'un de leurs procédés de préparation et les biomatériaux les contenant.
GB9325415D0 (en) 1993-12-13 1994-02-16 Res Inst Medicine Chem Chemical compounds
GB9405715D0 (en) 1994-03-23 1994-05-11 Res Inst Medicine Chem Chemical compounds
FR2733498B1 (fr) 1995-04-27 1997-05-30 Adir Nouveaux composes cyclohexaniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5723632A (en) 1996-08-08 1998-03-03 Mgi Pharma, Inc. Total synthesis of antitumor acylfulvenes
IT1287174B1 (it) 1996-11-15 1998-08-04 Angelini Ricerche Spa Diaril-ciclometilenpirazoli farmacologicamente attivi,procedimento per prepararli e composizioni farmaceutiche che li contengono
US5972998A (en) * 1997-05-23 1999-10-26 Hoechst Marion Roussel, Inc. Triptolide derivatives useful in the treatment of autoimmune diseases
EP1042285A4 (de) 1997-10-14 2002-11-20 Scripps Research Inst iso-CBI UND iso-CI ANALOGA VON CC-1065 UND DUOCARMYCINE
NZ504884A (en) 1997-12-08 2002-10-25 Scripps Research Inst Synthesis of the dihydroindole C-ring of CC-1065/duocarmycin analogs and certain intermediates
DE19855859A1 (de) 1998-12-03 2000-06-08 Degussa Katalysatoren für die enantioselektive Epoxidierung von C=C-Doppelbindungen
FR2787451B1 (fr) 1998-12-18 2001-01-26 Adir Nouveaux composes imidazoliniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AR023071A1 (es) 1998-12-23 2002-09-04 Syngenta Participations Ag Compuestos de piridincetona, compuestos intermediarios, composicion herbicida e inhibidora del crecimiento de plantas, metodo para controlar la vegetacion indeseada, metodo para inhibir el crecimiento de las plantas, y uso de la composicion para controlar el crecimiento indeseado de plantas.
US6331642B1 (en) 1999-07-12 2001-12-18 Hoffmann-La Roche Inc. Vitamin D3 analogs
AU2001296542B2 (en) 2000-10-02 2007-10-25 Emory University Triptolide analogs for the treatment of autoimmune and inflammatory disorders
US20040204394A1 (en) 2003-04-11 2004-10-14 Aderis Pharmaceuticals, Inc. Triptolide analogues

Also Published As

Publication number Publication date
US20030027806A1 (en) 2003-02-06
CA2424555A1 (en) 2002-04-11
US7557139B2 (en) 2009-07-07
EP1659125B1 (de) 2010-06-02
JP4269144B2 (ja) 2009-05-27
EP1330459A2 (de) 2003-07-30
ATE469907T1 (de) 2010-06-15
WO2002028862A2 (en) 2002-04-11
AU9654201A (en) 2002-04-15
US6777441B2 (en) 2004-08-17
US8193249B2 (en) 2012-06-05
DE60121986T2 (de) 2007-07-26
AU2001296542B2 (en) 2007-10-25
DE60142313D1 (de) 2010-07-15
JP2009102371A (ja) 2009-05-14
DE60121986D1 (de) 2006-09-14
JP2004525082A (ja) 2004-08-19
US20090234000A1 (en) 2009-09-17
US20060040907A1 (en) 2006-02-23
EP1330459B1 (de) 2006-08-02
WO2002028862A3 (en) 2002-09-12
EP1659125A1 (de) 2006-05-24
AU2001296542B9 (en) 2002-04-15

Similar Documents

Publication Publication Date Title
ATE334986T1 (de) Triptpolidanaloge zur verendung in der behandlung von autoimmunbedingten und entzündlichen erkrankungen
BRPI0407922A (pt) derivados de isoquinolina e métodos de uso destes
EE200300440A (et) Epotilooni analoogide ja kemoterapeutikumide kombinatsioon proliferatiivsete haiguste raviks
EE9900565A (et) Piperasiini derivaadid ja nende kasutamine põletikuvastaste vahenditena
CY2013041I2 (el) Φαρμακευτικες συνθεσεις περιλαμβανοντας δεξτρομεθορφανη και κινιδινη για την αγωγη νευρολογικων διαταραχων
DE69919580D1 (de) Verbindungen zur anwendung bei der behandlung entzündlicher erkrankungen
ATE407676T1 (de) Topoisomerasehemmern zur behandlung von chirurgischen verklebungen
ATE416761T1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
DE69736441D1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
ATE494904T1 (de) Verbindungen und verfahren zur erhöhung der neurogenese
ATE247117T1 (de) Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
EA200300566A1 (ru) Применение cci-779 в качестве противоопухолевого средства
DE69324859D1 (de) Verwendung von Lipid-gebundener Glykoaminoglykanen zur Behandlung der rheumatoider Arthritis
ATE453636T1 (de) Substituierte 2,3-dihydro-1h-isoindol-1-one derivate und anwendungsverfahren
ATE390133T1 (de) Gabapentinanaloga für schlafstörungen
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
SE9603669D0 (sv) New combination
ATE388708T1 (de) Piperazinderivate und anwendungsverfahren
EA200401183A1 (ru) Применение ингибиторов il-18 в качестве диагностического маркера
DE60333205D1 (de) Histaminika zur behandlung von allergischer rhinitis
NO984950L (no) Forbindelser med veksthormonfrigj°rende egenskaper
BRPI0408423A (pt) composições farmacêuticas compreendendo uma combinação de rapamicina ou seus derivados e pimecrolimus para o tratamento de doenças mediadas imunologicamente e por inflamação
DE60120961D1 (de) Disulfid-derivate verwendbar zur behandlung von allergischen erkrankungen
DE69932434D1 (de) Prophylaxe und Behandlung von autoimmunen Entmyelinisierungserkrankungen durch Fas-antagonisten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties